Sep 2026· International Journal of Radiation Oncology, Biology, Physics· 0 citations· 26 references
Medicine
TL;DR
The trend for tumour-to-kidney absorbed dose ratios should be weighed against other important aspects for radionuclide therapies, and considered with the uncertainty in the underlying assumption of equivalent biokinetics.
Abstract
INTRODUCTION
Biokinetics for potential alpha-emitter peptide receptor radionuclide therapies (PRRTs) were simulated to estimate tumour-to-kidney absorbed dose ratios for 225Ac, 227Th, 212Pb, 230U, 226Ac, 211At, and 149Tb. The impact of daughter redistribution was studied, along with the effects of differing biokinetics and modelling assumptions.
Methods
Post-injection whole body probe measurements and SPECT/CT images at five and four time points, respectively, of 14 patients receiving [177Lu]Lu-DOTATATE were used to estimate whole body, tumour, and kidney time-activity curves. Alpha-emitter PRRT biokinetics were estimated by adjusting time-activity curves by the physical half-lives of parent radionuclides. Daughter redistribution was included, assuming all alpha decays and separate scenarios with 0%, 16%, 36%, and 100% of beta decays released daughters to ICRP biokinetic models. The initial conditions of the biokinetic models were changed to assess the impact of modelling assumptions. The tumour-to-kidney absorbed dose ratios were compared. Variations between patients was assessed by coefficient of variation (CoV).
Results
Inter-patient variation in whole body time-integrated activities increased with physical half-life of the parent radionuclide. For 212Pb, 225Ac, and 227Th there was large inter-patient variation in kidney absorbed dose change when incorporating daughter redistribution (absolute CoV >40%), while for 226Ac and 230U it was consistent between patients (absolute CoV <3%). Modifying the distribution in the biokinetic models impacted the kidney absorbed dose, but different modifications impacted different decay chains. Tumour-to-kidney absorbed dose ratios tended to increase with parent half-life, but for some decay chains the effect of rate of daughter release from tumours was notable.
Conclusion
The trend for tumour-to-kidney absorbed dose ratios should be weighed against other important aspects for radionuclide therapies, and considered with the uncertainty in the underlying assumption of equivalent biokinetics. The large inter-patient variations resulting from daughter redistribution for 212Pb, 225Ac, and 227Th kidney absorbed doses underline the need for representative patient cohorts.
Radiopharmaceutical-therapy dosimetry depends on both radionuclide emission physics and the spatial distribution of activity. We evaluated how radionuclide identity and protein-defined subcellular localization influenced cancer-cell nuclear absorbed-dose distributions in one human breast-cancer region of interest...
Arvin Haj-Mirzaian, V. Onecha, Umar Mahmood et al.· EJNMMI Physics· 0 citations
The limited dosimetric impact from 118Te provides justification for its use as an in vivo generator of 118Sb for long-term PET, and the ADCs reported here offer a quantitative basis for assessing the dosimetric safety of 118Te radiopharmaceuticals.
Jaewoong Jang, Sotaro Miyao, Xin-Di Qiu et al.· Physics in Medicine and Biol...· 0 citations
The results support the further use of this approach for imaging autologous leukocytes using PET in a range of clinical and research settings and demonstrate the safety and favorable dosimetry of [89Zr]Zr-oxine-labeled leukocytes in healthy humans.
Kadir Gultekin, Jennifer L. Bartels, Carlos E. Cardenas et al.· European Journal of Nuclear...· 0 citations
Triple-negative breast cancer (TNBC) has limited targeted treatment options and is strongly influenced by stromal biology. This study evaluated [
177
Lu]Lu-FAPI for fibroblast activation protein-alpha (FAP)-directed tumor microenvironment targeting in TNBC models.
[
177
Lu]Lu-FAPI was assessed usin...
Zhi-Hua Tang, Lu-Shan Yu, Ke Zhang· Frontiers in Oncology· 0 citations
Purpose: This dosimetry study aimed to evaluate the organ-absorbed doses and safety profile of multiple doses of [177Lu]Ludotadipep, a novel PSMA-targeted radiopharmaceutical with an albumin-binding motif, in patients with metastatic androgen pathway modulator-resistant (mAPMR) prostate cancer. Methods: Twenty patients...
Seunggyun Ha, J. O, Chansoo Park et al.· Pharmaceutics· 0 citations
Neuroendocrine tumors (NETs) are often detected late, limiting curative treatments and requiring systemic therapies such as peptide receptor radionuclide therapy (PRRT). Although 177Lu-DOTATATE has demonstrated efficacy, its rapid clearance from the circulation limits tumor radiation delivery and may increase renal tox...
L. Bodei, Pat Zanzonico, Simone Krebs et al.· Journal of Nuclear Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.